Category Specific RSS

Categories: News

Blood test or crystal ball? Looking into the future of our health

An estimated 1.2 million Australians are living with diabetes, a serious chronic disease with numerous complications and comorbidities including diabetic kidney disease (DKD).

The risk factors for developing DKD are well known, but could we treat people better if we knew more about their personal risk factors, or predict the likelihood of future functional decline of the kidneys?

Proteomics International (ASX: PIQ) is answering that question with PromarkerD, a patented prodiagnostic test to predict the incidence of DKD in patients with type 2 diabetes and no existing DKD. The simple blood test detects a specific ‘fingerprint’ of the early onset of DKD by measuring biomarkers. The test also takes into account three routinely available clinical variables: age, HDL-cholesterol and estimated glomerular filtration rate (informs kidney function). The clinically validated diagnostic test has yielded good results, predicting up to 86% of otherwise healthy diabetics who then developed DKD within four years.

In order to bolster the tech, PIQ engaged life science company, Abcam to produce recombinant versions of the antibodies used in the PromarkerD test. These are more stable than those produced regularly resulting in a more consistent product.

To scale and expand availability of the test in the Northern Hemisphere, PIQ has contracted French immunoassay specialist Biotem to produce the PromarkerD test kits. Biotem is an international manufacturer of immunoassays and antibodies specifically designed for diagnostic tests.

Managing Director of Proteomics International, Dr. Richard Lipscombe said: “Currently, the PromarkerD immunoassay (ELISA) kits are manufactured under license in Australia. Now, by contracting these specialist manufacturers we are building our production capacity to meet our anticipated demand for the test in the Northern Hemisphere and worldwide.”

“The engagement of global manufacturing partners will help accelerate the worldwide roll-out of PromarkerD, as well as the commercialisation of our pipeline of other diagnostics under development.”

The three year agreement will run on a fee-for-service basis with the option for PIQ to extend for an additional period of one year.

Samantha Freidin

Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.

Recent Posts

Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise

Biotech company Biotron Limited (ASX:BIT) has announced a bold step into the anaesthetics sector, acquiring…

4 days ago

DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment

DroneShield (ASX:DRO) is expanding its Australian footprint with a $13 million investment to establish a…

2 weeks ago

Stakk Secures T-Mobile Contract to Power Super App Expansion

Australian fintech Stakk (ASX:SKK) has signed a three-year agreement with U.S. telecommunications giant T-Mobile USA,…

3 weeks ago

Medibank Backs Emyria with Landmark Depression Care Deal

Australia’s mental health burden is growing – and one of the toughest challenges is treatment-resistant…

4 weeks ago

NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI

NoviqTech Limited (ASX:NVQ) has taken a decisive step into the quantum computing market, unveiling the…

1 month ago

BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil

Brazilian Rare Earths Limited (ASX:BRE) has cleared its last regulatory hurdle to begin pilot operations…

2 months ago